Results 31 to 40 of about 1,741 (166)

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?

Respiratory Research, 2020
Despite treatment with standard-of-care medications, including currently available biologic therapies, many patients with severe asthma have uncontrolled disease, which is associated with a high risk of hospitalization and high healthcare costs. Biologic
Andrew Menzies-Gow, Michael E. Wechsler, Chris E. Brightling   +2 more
doaj   +1 more source

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Respiratory Research, 2020
Background Patients with severe, uncontrolled asthma have a significant unmet need for new treatments that have broader effects on airway inflammation, and that provide greater improvements in asthma outcomes than currently approved biologics and ...
Andrew Menzies-Gow, Gene Colice, Janet M. Griffiths, Gun Almqvist, Sandhia Ponnarambil, Primal Kaur, Gennaro Ruberto, Karin Bowen, Åsa Hellqvist, May Mo, Esther Garcia Gil   +10 more
doaj   +1 more source

Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives

Frontiers in Immunology, 2022
Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal antibodies that target key inflammatory cytokines involved in disease pathogenesis.
Grzegorz Kardas, Michał Panek, Piotr Kuna, Piotr Damiański, Maciej Kupczyk   +4 more
doaj   +1 more source

Tezepelumab treatment in severe asthma with recurrent chronic rhinosinusitis with nasal polyps: Case series

Journal of Allergy and Clinical Immunology: Global
Background: Tezepelumab is a human IgG2 mAb that inhibits thymic stromal lymphopoietin (TSLP) and is approved for treatment of severe asthma. Bronchial asthma, usually a type 2 inflammatory disease, often co-occurs with chronic rhinosinusitis with nasal ...
Yoshiro Kai, MD, PhD
doaj   +1 more source

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study

Journal of Asthma and Allergy, 2021
Jonathan Corren,1 Martin Karpefors,2 Åsa Hellqvist,3 Jane R Parnes,4 Gene Colice5 1Departments of Medicine and Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; 2Data Science and AI, AstraZeneca ...
Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G   +4 more
doaj  

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study

Journal of Asthma and Allergy, 2021
Claire Emson,1 Jonathan Corren,2 Kinga Sałapa,3 Åsa Hellqvist,4 Jane R Parnes,5 Gene Colice6 1Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca ...
Emson C, Corren J, Sałapa K, Hellqvist Å, Parnes JR, Colice G   +5 more
doaj  

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu, Houyong Li, Xicai Sun, Quan Liu, Yu Xu, Jiangang Fan, Andrew Foster, Claudia Chen, Yun Chon, Dehui Wang   +9 more
wiley   +1 more source

Inflammatory Signatures Beyond Th1/Th2 Endotypes Provide Insights Into Postoperative Recurrence in Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) represents a spectrum of inflammatory endotypes, driven by distinct T helper (Th) immune responses. The high rate of recurrent disease despite appropriate medical and surgical interventions highlights the need for improved characterization beyond the traditional type 2 and non‐type 2 phenotypes to better
Liyona Kampel, Narin N. Carmel, Shaun Edalati, Hen Chaushu, Forsan Jahshan, Yaniv Hadi, Timur Pestrikov, Leonor Leider Trejo, Nidal Muhanna, Avraham Abergel   +9 more
wiley   +1 more source

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those
Alisha Sharma, Alyssa Y. Li, Teruko Kishibe, Dennis Wong, Kevin M. Sanders, Maggie Jiang, Heedo Lee, Christine Song, Kieran Mcintyre, Christian Pagnoux, Yvonne Chan, John M. Lee, Daniel J. Lee   +12 more
wiley   +1 more source

Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies

Pulmonary Therapy
Introduction This post hoc analysis assessed the ability of tezepelumab treatment to restore normal lung function in patients with severe, uncontrolled asthma with abnormal lung function at baseline pooled from the PATHWAY and NAVIGATOR studies.
Ian D. Pavord, Christopher E. Brightling, Stephanie Korn, Nicole L. Martin, Sandhia S. Ponnarambil, Nestor A. Molfino, Jane R. Parnes, Christopher S. Ambrose   +7 more
doaj   +1 more source